Alkermes’ Corporate Presentation to be Webcast at the Leerink Swann 2012 Global Healthcare Conference

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Leerink Swann 2012 Global Healthcare Conference on Thursday, Feb. 16, 2012, at 3:00 p.m. EST (8:00 p.m. GMT) from the Waldorf=Astoria Hotel in New York City. The presentation may be accessed under the Investor tab on www.alkermes.com and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.



CONTACT:

Alkermes plc
Eva Stroynowski, +1 781-609-6823
Corporate Communications

KEYWORDS:   United Kingdom  United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Banking  Finance

MEDIA:

Logo
 Logo

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.